CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

CSL Limited is one of the world’s leading companies specializing in blood plasma therapies, nephrology, and vaccines. The ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

The City of Côte St. Luc and Mandevco, the developer of Quartier Cavendish, are not yet agreed on the city’s position ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

CSL’s shares (ASX: CSL) have started the year with the bears leading the way, with a 0.26% decline today bringing the cumulative YTD loss to 8.86%. With a new 52 week low of $253.04 being hit on the ...